BCAT-IN-4 Secrets
MI-CP151 was a period 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze to evaluate multiple intravenous doses of sifalimumab, in Grownup people with dermatomyositis or polymyositis (NCT00533091). Key demo aims were To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis sufferers